Click on image to view larger version.

Figure 1 Event-Free Survival After Randomization

Two-year adverse events in patients allocated to tirofiban + sirolimus-eluting stent (tirofiban + sirolimus-eluting stent [SES] group) and in patients randomized to abciximab infusion plus bare-metal stenting (abciximab + bare-metal stent [BMS] group). Cumulative risk of major adverse events (A), death or myocardial infarction (B), and target vessel revascularization (C).